Recurrent skin and soft tissue infections in HIV-infected patients during a 5-year period: incidence and risk factors in a retrospective cohort study

Vagish Hemmige1*, Moira McNulty2, Ethan Silverman2 and Michael Z. David2,3

Abstract

Background: Skin and soft tissue infections (SSTIs) are common in the era of community-associated methicillin resistant Staphylococcus aureus among HIV-infected patients. Recurrent infections are frequent. Risk factors for recurrence after an initial SSTI have not been well-studied.

Methods: Retrospective cohort study, single center, 2005–2009. Paper and electronic medical records were reviewed by one of several physicians. Subjects with initial SSTI were followed until the time of SSTI recurrence. Standard descriptive statistics were calculated to describe the characteristics of subjects who did and did not develop a recurrent SSTI. Kaplan-Meier methods were used to estimate the risk of recurrent SSTI. A Cox regression model was developed to identify predictors of SSTI recurrence.

Results: 133 SSTIs occurred in 87 individuals. 85 subjects were followed after their initial SSTI, of whom 30 (35.3 %) had a recurrent SSTI in 118.3 person-years of follow-up, for an incidence of second SSTI of 253.6 SSTIs/1000 person-years (95 % CI 166.8-385.7). The 1-year Kaplan-Meier estimated risk of a second SSTI was 29.2 % (95 % CI 20.3–41.0 %), while the 3-year risk was 47.0 % (95 % CI 34.4–61.6 %). Risk factors for recurrent SSTI in a multivariable Cox regression model were non-hepatitis liver disease (HR 3.44; 95 % CI 1.02–11.5; p = 0.05), the presence of an intravenous catheter (HR 6.50; 95 % CI 1.47–28.7; p = 0.01), and a history of intravenous drug use (IVDU) (HR 2.80; 95 % CI 1.02–7.65; p = 0.05); African-American race was associated with decreased risk of recurrent SSTI (HR 0.12; 95 % CI 0.04-0.41; p < 0.01). Some evidence was present for HIV viral load ≥ 1000 copies/mL as an independent risk factor for recurrent SSTI (HR 2.21; 95 % CI 0.99-4.94; p = 0.05). Hemodialysis, currently taking HAART, CD4+ count, trimethoprim-sulfamethoxazole or azithromycin use, initial SSTI type, diabetes mellitus, incision and drainage of the original SSTI, or self-report of being a man who has sex with men were not associated with recurrence.

Conclusion: Of HIV-infected patients with an SSTI, nearly 1/3 had a recurrent SSTI within 1 year. Risk factors for recurrent SSTI were non-hepatitis liver disease, intravenous catheter presence, a history of IVDU, and non-African-American race. Low CD4+ count was not a significant risk factor for recurrence.

Keywords: HIV, Epidemiology, Skin and soft tissue infections, MRSA

* Correspondence: vagish.hemmige@bcm.edu
1Division of Infectious Diseases, Department of Medicine, Baylor College of Medicine, 6620 Main, Suite 1375, Houston, TX 77030, USA
Full list of author information is available at the end of the article

© 2015 Hemmige et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

In 1998, the first increase in incidence of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in people without previous contact with the health care system was reported in children in Chicago [1]. Community-associated (CA-MRSA) infections were subsequently identified in other groups in the United States, especially marginalized populations, and CA-MRSA quickly became the leading cause of skin and soft tissue infections (SSTIs) with community onset among incarcerated populations and among impoverished urban populations [2, 3]. The advent of the CA-MRSA era dramatically affected the epidemiology of SSTIs, with a doubling in the number of SSTIs seen at safety net hospital emergency rooms [2].

Patients with human immunodeficiency virus (HIV) infection are particularly prone to infection with CA-MRSA because they are immunocompromised and because of demographic, behavioral, and socioeconomic factors as well as frequent exposures to the health care system [4, 5]. We have recently evaluated risk factors for a first SSTI among 511 HIV-infected patients in Chicago [6]. In that study, accounting for follow-up time, chronic skin conditions such as psoriasis and lymphedema, presence of an intravenous catheter, and lack of virologic suppression were most strongly associated with initial SSTI occurrence. There was also a trend toward an increased risk of SSTI in subjects receiving health insurance through Medicaid, the governmental health insurance program for the poor and disabled, and subjects with sexually transmitted diseases (STDs). Other studies have identified different risk factors [4], though our study differed methodologically from many other studies in that we identified all SSTIs which were documented in the medical record, not just SSTIs which were culture positive for *S. aureus*. This is important because in our study we found that cultures were more likely to be sent during an SSTI episode in patients with advanced immunocompromise [6]. Therefore, relying on culture data as a criterion for detection of an SSTI in retrospective studies may lead to biased conclusions about the epidemiology of SSTIs in the HIV-infected population. Although a number of anecdotal reports have suggested that recurrent SSTIs are common among HIV-infected patients [7, 8], few studies have examined the incidence of and risk factors for recurrent SSTIs in the HIV-infected population in the current era of CA-MRSA [9–12]. Accordingly, we set out to examine the risk factors for SSTI recurrence in an HIV-infected population receiving care at an urban tertiary care center clinic in the CA-MRSA era.

Methods

Study design

We performed a retrospective study of 511 HIV-infected adults (>18 years of age) who received their primary HIV care at the University of Chicago Medical Center’s (UCMC) Infectious Diseases Clinic for any period of time between January 1, 2005 and December 31, 2009. A description of this cohort has previously been published elsewhere [6]. SSTI was defined based on a physician diagnosis identified in medical record review. Recurrent SSTI was defined as either an SSTI at a new site or recurrence at the original site greater than 30 days after the initial SSTI with resolution of the signs and symptoms of the original infection in the interim. Individuals eligible for this study were those in the cohort who developed an SSTI and who accrued further follow-up time in the clinic after the initial SSTI. Subjects contributed follow-up time to this study from the day after the initial SSTI until either the occurrence of a first SSTI recurrence or until censoring. The study was approved by the Institutional Review Board of the Biological Sciences Division of the University of Chicago. Requirement for informed consent was waived.

Statistical methods

Proportions between groups were compared by the $\chi^2$ or Fisher’s exact test, as appropriate (i.e. if any cell in the appropriate 2 x N categorical table contained five or fewer subjects). Differences between groups of continuous outcomes were compared using the t-test or the Wilcoxon rank-sum test. Cox regression was used for time-to-event data to calculate the hazard ratio (HR) with 95 % confidence interval (CI) associated with various patient characteristics [13]. The overall fit of potential Cox models was assessed via a plot of the Nelson-Aalen cumulative hazard against Cox-Snell residuals [14, 15]. The proportional hazards assumption was verified in potential models via the use of log-log plots, and the presence or lack of influential observations was verified by calculating DFBETAs for each potential predictor [15]. Incidence rates were calculated using cluster-adjusted Poisson regression [16]. Based on exploratory analysis, we chose to categorize viral load as a binary variable with cutoff of 1000 copies/mL. CD4+ count was similarly categorized as a binary variable with cutoff of 100 cells/mL. Patients who had greater than 365 days without a measured CD4+ count or HIV viral load (VL) were deemed to have been lost to follow-up for that period and were interval censored in the statistical analysis [17]. All analyses were performed using Stata 12 (Statacorp; College Station, TX).

Results

Population characteristics

Of the 511 subjects in the initial cohort, 87 individuals (17.0 %) experienced at least one SSTI as described elsewhere [6]. Two subjects from the cohort had no follow-up time after the initial SSTI, so 85 subjects were...
included in the analysis reported in this study. The demographics of this cohort are shown in Table 1. The 85 subjects contributed 118.3 person-years of follow-up, with subjects censored at loss to follow-up or at the time of recurrent SSTI.

Of the initial SSTIs, 50 (58.8 %) were abscesses, 27 (31.8 %) were furuncles, and 8 (9.4 %) were cellulitides. Incision and drainage of the initial SSTI was performed in 28 cases (32.9 %). Only 23/85 initial SSTIs were associated with culture data, one of which was culture-negative. S. aureus was an identified pathogen in 15 initial SSTIs, and MRSA in 11 of these. Pseudomonas aeruginosa was the only other pathogen identified in more than one patient, having been identified in 3 SSTIs. All cultures were from an infected skin site.

Of the 85 initial SSTIs, 20 (23.5 %) were treated with combination antimicrobial drug therapy. The most common combination used was ciprofloxacin and clindamycin, used in 3 patients (3.5 % of all patients, 15 % of patients receiving combination therapy). Of the 65 who did not receive combination antimicrobial drug therapy, 20 (23.5 % of all initial SSTIs) received a beta-lactam, 21 (24.7 %) received clindamycin, 8 (9.4 %) received trimethoprim-sulfamethoxazole, 5 (5.9 %) received a fluoroquinolone, 2 (2.4 %) received vancomycin, and 3 (3.5 %) received no antimicrobial drug therapy. Whether or not antimicrobial drug therapy was prescribed for the initial SSTI was not documented in the medical records of six (7.1 %) patients. As documented in the medical record, no subject underwent attempts at decolonization after the initial SSTI.

A total of 30 subjects among the 85 who had follow-up (35.3 %) experienced at least one recurrent SSTI during follow-up. Using Kaplan-Meier methods, the estimated proportion of individuals who would have experienced a recurrent SSTI if all individuals had been followed for one year was 29.2 % (95 % CI 20.3 %-41.0 %), while the 3-year risk was 47.0 % (95 % CI 34.4 %-61.6 %). Figure 1 shows the estimated Kaplan-Meier cumulative incidence of SSTIs over time. The incidence of second SSTI was 253.6 SSTIs/1000 person-years (95 % CI 166.8-385.7). Fourteen subjects experienced multiple recurrences (16.5 % of all subjects with initial SSTI; 46.7 % of subjects with at least one recurrence).

A number of variables assessed as potential risk factors for SSTIs were time-varying. These variables were therefore not assumed to be present throughout the follow-up period; instead, they were calculated as present or absent on each day of follow-up. For example, 79.8 % of follow-up time accrued to individuals on Medicaid, 1.6 % to individuals with a catheter, 24.7 % to individuals taking trimethoprim-sulfamethoxazole prophylaxis, and 12.0 % to individuals taking azithromycin prophylaxis. Highly active antiretroviral therapy (HAART) was being given 77.1 % of the time, and the cohort had an HIV VL < 1000 copies/mL on 60.0 % of days. The diagnosis of certain comorbid conditions was assessed similarly, with 14.6 % of follow-up time occurring in subjects with diabetes, and 7.8 % with cancer (Table 2).

**Characteristics of recurrent SSTIs**
The median recurrent SSTI occurred at 144 days after the initial SSTI (interquartile range [IQR], 89–377). Trimethoprim-sulfamethoxazole prophylaxis was being taken by 5/30 subjects (16.7 %) at the time of SSTI, and 3/6 (50 %) individuals with CD4+ count < 200 cells/mm³ at the time of SSTI were taking trimethoprim-sulfamethoxazole. The median CD4+ count at the time of recurrent SSTI was 403.5 (IQR 239–529), and the median VL was 1475 copies/mL (IQR undetectable-27800). We found that 26/30 (86.7 %) SSTI recurrences occurred in patients with CD4+ count > 100 cells/mm³. Of the recurrent infections, 17 were abscesses (56.7 %), 9 were cellulitis (30.0 %), and 3 were furuncles (10.0 %), and the type of SSTI was undocumented in one case. 13 of 30 (43.3 %) recurrent infections met Centers for Disease Control and Prevention (CDC) criteria for a community-associated SSTI (CA-SSTI) [18]. The primary reason that an SSTI was not classified as a CA-SSTI was hospitalization within the prior year, which was the case in 12/30 (40.0 %) patients.

Culture data were only obtained for 8 of the recurrent SSTIs, and of those, 6 of the 8 (75 %) were confirmed S. aureus infections, with 4 of the 6 (67 %) being MRSA. Of those 4 infections, 3 were clindamycin-susceptible MRSA, and all four were susceptible to trimethoprim-sulfamethoxazole. Of the 6 culture-proven S. aureus infections, only 1 MRSA SSTI met CDC criteria for being a CA-SSTI. The other two SSTIs were caused by Proteus and a coagulase negative staphylococcus species. Three of the six recurrent SSTIs caused by S. aureus were associated with culture data for the initial SSTI; all three initial SSTIs were caused by S. aureus as well. In two patients, both infections were causes by MRSA, and in one patient, both infections were causes by MSSA.

Therapy in cases of recurrent SSTI was with a beta-lactam in five cases (16.7 %), combination therapy in seven cases (23.3 %), clindamycin in four cases (13.3 %), TMP-SMX in three cases (10 %), levofloxacin in one case (3.3 %), and vancomycin in one case (3.3 %). Five patients (16.7 %) received no systemic antibacterial therapy, and antibiotic therapy was not documented in four cases (13.3 %).

**Predictors of Recurrent SSTI**
The results of univariate Cox regression with possible predictors of SSTI are listed in Table 3. At any given time point, the presence of an intravascular catheter (HR 4.62; 95 % confidence intervals [CI] 1.08-19.7; p = 0.04), chronic
### Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period

| Baseline variable                      | No recurrent SSTI (n = 55) | Had recurrent SSTI (n = 30) | Total (n = 85) |
|----------------------------------------|----------------------------|-----------------------------|---------------|
| Sex                                    |                            |                             |               |
| Male                                   | 30 (65.2 %)                | 16 (34.8 %)                 | 46 (54.1 %)   |
| Female                                 | 25 (64.1 %)                | 14 (35.9 %)                 | 39 (45.9 %)   |
| Sexual behavior                        |                            |                             |               |
| Male                                   | 30 (65.2 %)                | 16 (34.8 %)                 | 46            |
| Sex with men and women                 | 6 (75.0 %)                 | 2 (25.0 %)                  | 8 (17.4 %)    |
| Sex with men                           | 11 (64.7 %)                | 6 (35.3 %)                  | 17 (36.7 %)   |
| Sex with women                         | 13 (61.9 %)                | 8 (38.1 %)                  | 21 (45.7 %)   |
| Female                                 | 25 (64.1 %)                | 14 (35.9 %)                 | 39            |
| Sex with women                         | 1 (100 %)                  | 0 (0 %)                     | 1 (2.6 %)     |
| Sex with men                           | 24 (63.2 %)                | 14 (36.8 %)                 | 38 (97.4 %)   |
| Mean initial age (sd)                  | 40.7 (1.5)                 | 40.1 (1.9)                  | 40.5 (1.2)    |
| Median initial CD4 (IQR)               | 363 (180–553)              | 351 (242–542)               | 353 (199–552) |
| Initial VL at time of first SSTI       |                            |                             |               |
| <1000                                   | 28 (70.0 %)                | 12 (30.0 %)                 | 40 (47.1 %)   |
| 1000+                                   | 27 (60.0 %)                | 18 (40.0 %)                 | 45 (52.9 %)   |
| IVDU history                           |                            |                             |               |
| No                                     | 49 (67.1 %)                | 24 (32.9 %)                 | 73 (86.9 %)   |
| Yes                                    | 5 (45.4 %)                 | 6 (54.6 %)                  | 11 (13.1 %)   |
| Inhaled drug use                       |                            |                             |               |
| No                                     | 41 (64.1 %)                | 23 (35.9 %)                 | 64 (76.2 %)   |
| Yes                                    | 13 (65.0 %)                | 7 (35.0 %)                  | 20 (23.8 %)   |
| Methamphetamine use                   |                            |                             |               |
| No                                     | 54 (65.1 %)                | 29 (34.9 %)                 | 83 (98.8 %)   |
| Yes                                    | 0 (0 %)                    | 1 (100 %)                   | 1 (1.2 %)     |
| Incarceration                          |                            |                             |               |
| No                                     | 47 (61.8 %)                | 29 (38.2 %)                 | 76 (90.5 %)   |
| Yes                                    | 7 (87.5 %)                 | 1 (12.5 %)                  | 8 (9.5 %)     |
| Race                                   |                            |                             |               |
| African-American                       | 52 (67.5 %)                | 25 (32.5 %)                 | 77 (91.7 %)   |
| Caucasian                              | 2 (40.0 %)                 | 3 (60.0 %)                  | 5 (5.9 %)     |
| Hispanic                               | 1 (50.0 %)                 | 1 (50.0 %)                  | 2 (2.4 %)     |
| Educational status                     |                            |                             |               |
| Did not complete high school           | 5 (83.3 %)                 | 1 (16.7 %)                  | 6 (22.2 %)    |
| High school graduate                   | 1 (33.3 %)                 | 2 (66.7 %)                  | 3 (11.1 %)    |
| Some college                           | 8 (66.7 %)                 | 4 (33.3 %)                  | 12 (44.4 %)   |
| College graduate                       | 4 (66.7 %)                 | 2 (33.3 %)                  | 6 (22.2 %)    |
| Employment during follow-up            |                            |                             |               |
| No                                     | 32 (64.0 %)                | 18 (36.0 %)                 | 50 (59.5 %)   |
| Yes                                    | 22 (64.7 %)                | 12 (35.3 %)                 | 34 (40.5 %)   |
| Chronic skin disease                   |                            |                             |               |
| No                                     | 38 (69.1 %)                | 17 (30.9 %)                 | 55 (64.7 %)   |
| Yes                                    | 17 (56.7 %)                | 13 (43.3 %)                 | 30 (35.3 %)   |
|                  | Did not develop recurrent SSTI | Developed recurrent SSTI | Total n (%) |
|------------------|-------------------------------|---------------------------|-------------|
| **Hepatitis C**  |                               |                           |             |
| No               | 47 (64.4 %)                   | 26 (35.6 %)               | 73 (85.9 %) |
| Yes              | 8 (66.7 %)                    | 4 (33.3 %)                | 12 (14.1 %) |
| **Non-hepatitis liver disease** |                           |                           |             |
| No               | 54 (67.5 %)                   | 26 (32.5 %)               | 80 (94.1 %) |
| Yes              | 1 (20.0 %)                    | 4 (80.0 %)                | 5 (5.9 %)   |
| **Initial SSTI type** |                           |                           |             |
| Abscess          | 28 (56.0 %)                   | 22 (44.0 %)               | 50 (58.8 %) |
| Furuncle         | 20 (74.1 %)                   | 7 (25.9 %)                | 27 (31.8 %) |
| Cellulitis       | 7 (87.5 %)                    | 1 (12.5 %)                | 8 (9.4 %)   |
| **Incision and drainage performed** |                           |                           |             |
| No               | 41 (71.9 %)                   | 16 (28.1 %)               | 57 (67.1 %) |
| Yes              | 14 (50.0 %)                   | 14 (50.0 %)               | 28 (32.9 %) |
| **Initial SSTI S aureus** |                           |                           |             |
| No               | 48 (68.6 %)                   | 22 (31.4 %)               | 70 (82.4 %) |
| Yes              | 7 (46.7 %)                    | 8 (26.7 %)                | 15 (17.7 %) |
| **Initial SSTI MRSA** |                           |                           |             |
| No               | 50 (67.6 %)                   | 24 (32.4 %)               | 74 (87.1 %) |
| Yes              | 5 (45.5 %)                    | 6 (54.5 %)                | 11 (12.9 %) |
| **Initial SSTI Treatment** |                           |                           |             |
| Combination therapy | 11 (55.0 %)                   | 9 (45.0 %)                | 20 (23.5 %) |
| Beta-lactam      | 12 (60.0 %)                   | 8 (40.0 %)                | 20 (23.5 %) |
| Clindamycin      | 16 (76.2 %)                   | 5 (23.8 %)                | 21 (24.7 %) |
| Fluoroquinolone  | 4 (80.0 %)                    | 1 (20.0 %)                | 5 (5.9 %)   |
| Trimethoprim- sulfamethoxazole | 5 (62.5 %)                   | 3 (37.5 %)                | 8 (9.4 %)   |
| Vancomycin       | 2 (100 %)                     | 0 (0 %)                   | 2 (2.3 %)   |
| None             | 3 (100 %)                     | 0 (0 %)                   | 3 (3.5 %)   |
| Unknown          | 2 (33.3 %)                    | 4 (66.7 %)                | 6 (7.1 %)   |
| **Chlamydia since 2004** |                           |                           |             |
| No               | 52 (64.2 %)                   | 29 (35.8 %)               | 81 (95.3 %) |
| Yes              | 3 (75.0 %)                    | 1 (25.0 %)                | 4 (4.7 %)   |
| **Gonorrhea since 2004** |                           |                           |             |
| No               | 54 (65.1 %)                   | 29 (34.9 %)               | 83 (97.7 %) |
| Yes              | 1 (50.0 %)                    | 1 (50.0 %)                | 2 (2.3 %)   |
| **Syphilis since 2004** |                           |                           |             |
| No               | 50 (63.3 %)                   | 29 (36.7 %)               | 79 (92.9 %) |
| Yes              | 5 (83.3 %)                    | 1 (16.7 %)                | 6 (7.1 %)   |
| **Human papilloma virus (Clinical) since 2004** |                           |                           |             |
| No               | 47 (65.3 %)                   | 25 (34.7 %)               | 72 (84.7 %) |
| Yes              | 8 (61.5 %)                    | 5 (38.5 %)                | 13 (15.3 %) |
| **Human papilloma virus (Pap) since 2004** |                           |                           |             |
| No               | 45 (64.3 %)                   | 25 (35.7 %)               | 70 (82.4 %) |
| Yes              | 10 (66.7 %)                   | 5 (33.3 %)                | 15 (27.6 %) |
Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period (Continued)

| Characteristic                                      | No (n, %) | Yes (n, %) | Total (n, %) |
|-----------------------------------------------------|-----------|------------|--------------|
| Trichomonas since 2004                              | 47 (61.8 %) | 29 (38.2 %) | 76 (89.4 %)  |
|                                                     | 8 (88.9 %)  | 1 (11.1 %)  | 9 (10.6 %)   |
| Any sexually transmitted disease since 2004         | 29 (59.2 %) | 20 (40.8 %) | 49 (57.7 %)  |
|                                                     | 26 (72.2 %) | 10 (27.8 %) | 36 (42.4 %)  |
| Pneumocystic jirovecii since 2004                   | 54 (65.8 %) | 28 (34.2 %) | 82 (96.5 %)  |
|                                                     | 1 (33.3 %)  | 2 (66.7 %)  | 3 (3.5 %)    |
| Non-tuberculous mycobacteria since 2004            | 53 (63.9 %) | 30 (36.1 %) | 83 (97.7 %)  |
|                                                     | 2 (100.0 %) | 0 (0.0 %)   | 2 (2.4 %)    |
| Cytomegalovirus since 2004                          | 54 (64.3 %) | 30 (35.7 %) | 84 (98.8 %)  |
|                                                     | 1 (100.0 %) | 0 (0.0 %)   | 1 (1.2 %)    |
| Cryptococcus since 2004                             | 53 (64.6 %) | 29 (35.4 %) | 82 (96.5 %)  |
|                                                     | 2 (66.7 %)  | 1 (33.3 %)  | 3 (3.5 %)    |
| Initial TMP-SMX use                                 | 41 (65.1 %) | 22 (34.9 %) | 63 (74.1 %)  |
|                                                     | 14 (63.6 %) | 8 (36.4 %)  | 22 (25.9 %)  |
| Initial azithromycin use                            | 48 (63.2 %) | 28 (36.8 %) | 76 (89.4 %)  |
|                                                     | 7 (77.8 %)  | 2 (22.2 %)  | 9 (10.6 %)   |
| Initial HAART use                                   | 13 (52.0 %) | 12 (48.0 %) | 25 (29.4 %)  |
|                                                     | 42 (70.0 %) | 18 (30.0 %) | 60 (70.6 %)  |
| Initial catheter presence                           | 54 (65.9 %) | 28 (34.1 %) | 82 (96.5 %)  |
|                                                     | 1 (33.3 %)  | 2 (66.7 %)  | 3 (3.5 %)    |
| Initial insurance Medicaid                          | 16 (64.0 %) | 9 (36.0 %)  | 25 (29.4 %)  |
|                                                     | 39 (65.0 %) | 21 (35.0 %) | 60 (70.6 %)  |
| Initial cancer status                               | 50 (63.3 %) | 29 (36.7 %) | 79 (92.9 %)  |
|                                                     | 5 (83.3 %)  | 1 (16.7 %)  | 6 (7.1 %)    |
| Initial diabetes                                    | 48 (65.8 %) | 25 (34.3 %) | 73 (85.9 %)  |
|                                                     | 7 (58.3 %)  | 5 (41.7 %)  | 12 (14.1 %)  |
| Initial ESRD status                                 | 48 (65.8 %) | 25 (34.3 %) | 73 (85.9 %)  |
|                                                     | 7 (58.3 %)  | 5 (41.7 %)  | 12 (14.1 %)  |
liver disease (HR 2.89; 95 % CI 1.00-8.35, \( p = 0.05 \)), and lymphedema (HR 4.12; 95 % CI 1.24-14.1; \( p = 0.02 \)) were associated with an increased risk of recurrent SSTI, while African-American race was associated with decreased risk of recurrent SSTI (HR 0.34; 95 % CI 0.11-1.00; \( p = 0.05 \)).

Predictors with \( p < 0.2 \) were candidates for the final multivariate Cox model, which was developed by a forward selection algorithm. Significant predictors as well as theoretical concerns led to the choice of our final model for multivariate regression. For example, we found a strong association between lymphedema and intravenous drug use (IVDU) in our cohort; we accordingly only included IVDU in the final model to avoid collinearity.

Similarly, although gonorrhea was a strong statistical predictor of recurrent SSTI in several preliminary multivariate models, we found that models including gonorrhea were overly influenced by the single subject with a history of gonorrhea during follow up with recurrent SSTI (out of two subjects with a history of gonorrhea during follow up). Accordingly, gonorrhea was not included in the final model as it was felt that the data were inadequate to allow for a multivariable analysis including this predictor. Risk factors for recurrent SSTI in the final multivariable Cox regression model were non-hepatitis liver disease (HR 3.44; 95 % CI 1.02-11.5; \( p = 0.05 \)), the presence of an intravenous catheter (HR 6.50; 95 % CI 1.47-28.7; \( p = 0.01 \)), and a history of intravenous drug use (HR 2.80; 95 % CI 1.02-7.65; \( p = 0.05 \)); African-American race remained associated with a decreased risk (HR 0.17; 95 % CI 0.05-0.54; \( p < 0.01 \)). A trend was present for HIV viral load \( \geq 1000 \) copies/mL as an independent risk factor for recurrent SSTI (HR 2.21; 95 % CI 0.99-4.94; \( p = 0.05 \)), which was nearly statistically significant. A Cox-Snell residual plot demonstrated that the model fit the data well (plot not shown).

As a sensitivity analysis, we repeated the above analyses but used 30-, 60-, 90- and 365-day recent averages for a number of the above time-varying factors, without significant change in the results (data not shown). Similarly, we used linearly extrapolated CD4+ counts and HIV VLs and found that point estimates did not change significantly. As a final sensitivity analysis, we used CD4+ count of 200 as an alternative cutoff, without significant change in the results.

**Discussion**

In an urban, primarily African-American cohort, we confirmed that patients infected with HIV who had a medically attended SSTI had a high rate of subsequent SSTI, with most recurrences diagnosed within months
of the initial SSTI. We identified risk factors for recurrence which do not entirely overlap the risk factors for initial SSTI found in our previous paper [19] or in the work of others [20], though our studies differed from most other studies in examining all subjects with SSTIs, not just those with proven MRSA SSTIs. It may be that the risk factors for initial SSTI occurrence differ from those that predispose to continued colonization with or re-exposure to pathogenic bacteria.

In our cohort, African Americans, who constituted more than 90 % of the patient sample, demonstrated a significantly lower rate of recurrent SSTI as compared with others. We surmise that the risk factors leading to initial SSTIs in those not of African-American descent in our cohort may be more strongly associated with the risk of SSTI recurrence than the risk factors leading to initial SSTI in African Americans. However, our sample of non-African Americans is too small to permit rigorous testing of this hypothesis. Previous observational cohorts have noted that African-Americans are less likely to remain in care [21], but differential rates of follow-up for African-Americans would only explain our results if African Americans having recurrent SSTIs were more likely than other African Americans to be lost to follow-up. We also found that established risk factors for SSTI recurrence such as intravenous drug use and presence of an intravenous catheter [8] predicted SSTI recurrence.

Some of our preliminary modelling suggested an independent impact of a gonorrhea diagnosis, although the STD incidence observed in our population was too low to assess reliably the effect of STD diagnosis on SSTI recurrence risk. It has been proposed that ongoing high risk sexual behavior may re-expose HIV-infected patients to pathogenic strains of MRSA. Prior studies by other researchers have found that many HIV-infected

| Table 3 Predictors of risk of recurrent SSTI in univariate and multivariate Cox regression models |
| --- |
| Factor | Univariate HR (95 % CI) | p-value | Multivariate HR (Final model) (95 % CI) | p-value |
| HAART | 0.67 (0.31–1.44) | 0.30 | | |
| Trimethoprim-sulfamethoxazole | 0.73 (0.28–1.91) | 0.52 | | |
| Azithromycin | 1.38 (0.48–3.98) | 0.55 | | |
| Age (cont) | 0.99 (0.96–1.03) | 0.71 | | |
| STD (any) | 1.06 (0.49–2.27) | 0.88 | | |
| Chlamydia | 1.18 (0.16–8.77) | 0.87 | | |
| Gonorrhea | 4.96 (0.65–37.7) | 0.12 | | |
| Syphilis | 0.49 (0.07–3.59) | 0.48 | | |
| Human papilloma virus (clinical) | 1.58 (0.60–4.17) | 0.35 | | |
| Human papilloma virus (Pap) | 1.12 (0.43–2.92) | 0.82 | | |
| Trichomonas | 0.45 (0.06–3.33) | 0.44 | | |
| Catheter | 4.62 (1.08–19.7) | 0.04 | 6.50 (1.47–28.7) | 0.01 |
| Medicaid | 0.64 (0.30–1.37) | 0.25 | | |
| End stage renal disease | 0.70 (0.16–2.93) | 0.62 | | |
| Cancer | 0.51 (0.07–3.73) | 0.51 | | |
| Diabetes | 1.03 (0.39–2.69) | 0.96 | | |
| Hepatitis B | 1.27 (0.38–4.20) | 0.69 | | |
| Hepatitis C | 0.91 (0.32–2.61) | 0.86 | | |
| Incarceration | 0.22 (0.03–1.65) | 0.14 | | |
| Other chronic liver disease | 2.89 (1.00–8.35) | 0.05 | 3.43 (1.02–11.5) | 0.05 |
| Men who have sex with men | 0.81 (0.36–1.81) | 0.60 | | |
| IVDU | 2.41 (0.98–5.91) | 0.06 | 2.80 (1.02–7.65) | 0.05 |
| Male | 0.87 (0.42–1.79) | 0.71 | | |
| African-American race | 0.34 (0.11–1.00) | 0.05 | 0.12 (0.03–0.41) | <0.01 |
| Chronic skin disease: Any | 1.36 (0.66–2.79) | 0.41 | | |
| Psoriasis | 0.46 (0.06–3.39) | 0.45 | | |
| Lymphedema | 4.12 (1.24–14.1) | 0.02 | | |
| CD4 100+ | Reference | | | |
| <100 | 1.13 (0.39–3.24) | 0.83 | | |

| Table 3 Predictors of risk of recurrent SSTI in univariate and multivariate Cox regression models (Continued) |
| --- |
| Viral load | Univariate HR (95 % CI) | p-value | Multivariate HR (Final model) (95 % CI) | p-value |
| <1000 | Reference | | | |
| 1000+ | 1.58 (0.99–4.94) | 0.05 | | |
| Initial SSTI type | | | | |
| Abscess | Reference | | | |
| Furuncle | 0.26 (0.03–1.91) | 0.19 | | |
| Cellulitis | 0.66 (0.28–1.55) | 0.34 | | |
| Incision and drainage performed on initial SSTI | 1.69 (0.82–3.47) | 0.15 | | |
| Initial SSTI | S. aureus | 2.10 (0.93–4.72) | 0.07 | | |
| Initial SSTI MRSA | 2.21 (0.90–5.40) | 0.08 | | |
patients only demonstrate groin colonization with MRSA without colonization at other sites [22]. The occurrence of gonorrhea or other STDs may serve as a marker of continuing exposure to other colonized individuals, leading to reacquisition of pathogenic strains and predisposing towards SSTI recurrence.

We found that non-hepatitis liver disease, which in our cohort was predominantly due to alcoholic liver disease, was a risk factor for recurrent SSTI. Although not previously described specifically as a risk factor for recurrent SSTI in HIV-infected populations, the association between cirrhosis and SSTI risk has been previously described by other authors [23].

We were unable to test the finding of others that treatment of the initial SSTI with minocycline reduces the risk of recurrence [11] because only one patient in our study received minocycline as the treatment for the initial SSTI, which reflects institutional preferences for certain antimicrobials for the treatment of SSTIs at our center.

Our finding that lack of virologic control, better than CD4+ lymphocyte count per se, predicted SSTI risk is difficult to explain but is consistent with the findings of other authors [10]. This effect may be related to the immunologic effect of uncontrolled HIV replication. Alternatively, unsuppressed viral load, a marker of poor adherence to medication, may serve as a marker of patients who are not taking trimethoprim-sulfamethoxazole prophylaxis to prevent pneumocystis pneumonia, which potentially may also be protective against SSTI [24, 25]. Alternatively, lack of virologic suppression may be a marker of other behavioral and demographic risk factors for SSTI.

Our study is one of only six in which authors have examined SSTI recurrence in HIV-infected adults (Table 4).斯基斯特等进行了在达拉斯的一个城市中心的前瞻性研究，包括患有初始S. aureus皮肤感染的门诊患者在2003–2004 [12]。复发性SSTI被记录在11/37的患者（29.7 %）。调整变量长度的随访后，初始SSTI没有被记录。是否不适当的抗菌治疗被开具并且是否不进行切开和吸引没有被记录。没有额外的统计分析用于风险因素的分析。

格伯等进行了一个中心的回顾性研究在城市的一个公共中心，包括患有初始MRSA感染的门诊患者在2002–2006 [9]。患者被跟踪至2007年。一个复发性SSTI被记录在44/62的患者（71.0 %）。调整变量长度的随访后，初始SSTI没有被记录。复发的中位时间是135.5天，这与我们在研究中的发现相似。Cox回归分析中，表观光和临床预测因子没有显示出显著的预测SSTI复发。在62名患者中，与最初的MRSA SSTI相比，17（27 %）名患者发展为复发。

Vyas et al. performed a single-center retrospective study at a military-affiliated HIV clinic in San Diego, accruing patients with initial MRSA SSTI in 2003–2010 [7, 11]. Patients were followed through 2010. Of 63 patients with initial MRSA SSTI, 17 (27 %) experienced a recurrent MRSA SSTI. Adjustment for variable length of follow-up after the initial SSTI was not performed. The lower rate of recurrence in this study may have resulted from the inclusion of only culture-proven recurrences. Incision and drainage was not associated with a decreased risk of recurrence. Use of an antibiotic other than minocycline and hospitalization for the initial SSTI were significant risk factors for recurrence in a multivariable analysis (Table 4). Patients with a recurrent SSTI demonstrated a significantly lower CD4+ count in a mixed-effects model using CD4+ lymphocyte count as the outcome.

Crumb-Cianflone等进行了在一个中心的回顾性研究在军事附属的HIV医院在圣地亚哥，包括患有初始MRSA SSTI的患者在2000–2007 [10]。这项研究是在相同的中心进行的Vyas的研究，在一个重叠的时间框架。31名患者中，14（41 %）名患者有复发性SSTI。在我们研究中观察到的复发性SSTI的比率与在Vyas的研究中记录的比率相似。如果CD4+计数在混合效应模型中使用CD4+淋巴细胞计数作为结果变量，则仅HIV VL > 1000 copies/mL是一个显著的预测因子。

Crumb-Cianflone等从美国军事HIV自然历史研究中收集了数据，这是一个中心的多中心前瞻性研究，从2006年到2010年 [26]。379名患者中，31 %的患者在初次SSTI后3个月内出现复发。这些患者没有被识别到具有统计学意义的风险因素。

我们的研究被限制为是一个单中心回顾性的医疗记录回顾。因此，一些 demographic information was missing. The diagnosis and outcome of SSTI was based on physician documentation. Older paper records were incomplete. SSTIs diagnosed at centers other than our own were missed, and so our estimate of SSTI recurrence risk was likely a lower bound.

We have no specific data on how often patients in our cohort sought care elsewhere. There are community hospitals with emergency departments but no other major
tertiary care centers within five miles of our center. Cox regression requires an assumption of non-informative censoring (i.e., that subjects who are lost to follow-up are similar in their characteristics to those who remain engaged in care), and the results of our analysis may be biased to the extent that this assumption is violated. However, the problem of loss to follow-up is inherent to any study of urban HIV-infected populations [27].

Conclusions
This study contributes to the literature as one of the few analyses of risk factors for recurrence of SSTI in an urban, socioeconomically diverse cohort of HIV-infected adults. Our study is unique in that most previous studies on this topic have only included subjects whose initial SSTIs were culture-proven *S. aureus* SSTIs, while our study includes all subjects in our cohort with an initial SSTI. Our investigation improves on other studies by explicitly accounting for time-varying predictor variables and for variable time of follow-up using Kaplan-Meier methods and by following patients for a relatively long period of time. Further work to define risk factors for SSTI recurrence will enable physicians to target potential preventative interventions to those HIV-infected individuals at highest risk of SSTI recurrence.

Abbreviations
MRSA: Methicillin-resistant *Staphylococcus aureus*; CA-MRSA: Community-associated methicillin-resistant *Staphylococcus aureus*; SSTI: Skin and soft tissue infection; STD: Sexually transmitted disease; HIV: Human immunodeficiency virus; VL: Viral load; HR: Hazard ratio; CI: Confidence interval; IVDU: Intravenous drug use; HAART: Highly active antiretroviral therapy; OI: Opportunistic infection; IQR: Interquartile range; CA-SSTI: Community-associated skin and soft tissue infection.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
M2D conceived of the study, VH and M2D designed the study, VH, MM, and ES collected the data. VH and M2D performed the statistical analysis. All authors contributed to data analysis and interpretation. VH wrote the first manuscript draft. All authors contributed to the final manuscript. All authors read and approved the final manuscript.

Acknowledgements
Richard Rodgers provided invaluable assistance in the data collection process. Preliminary data from this study were presented as an abstract at ID Week 2014, Philadelphia, PA, October 8–12, 2014. Michael David acknowledges funding from NIH NIAID grant K23 AI095361

Author details
1Division of Infectious Diseases, Department of Medicine, Baylor College of Medicine, 6620 Main, Suite 1375, Houston, TX 77030, USA. 2Department of Medicine, University of Chicago, 5841 S Maryland, Chicago, IL 60637, USA. 3Department of Pediatrics and Department of Public Health Sciences, University of Chicago, 5841 S. Maryland Ave. MC6054, Chicago 60637, USA.

Received: 17 March 2015 Accepted: 14 October 2015

References
1. Herold BC, Immergluck LC, Maranan MC, Laundera DC, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593–8.
2. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309–17.
3. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616–67. doi:10.1128/ cmr.00081-10.
4. Imaz A, Pujol M, Barragan P, Dominguez MA, Titaboschi JM, Podzamczer D. Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients. AIDS Rev. 2010;12(3):153–63.
5. Cole J, Popovich K. Impact of community-associated methicillin-resistant Staphylococcus aureus on HIV-infected patients.Curr HIV/AIDS Rep. 2013;10(3):244–53. doi:10.1007/s11606-013-9161-0.
6. Hemmige V, McNulty M, Silverman E, David MZ. Predictors of skin and soft tissue infections in HIV-infected outpatients in the community-associated methicillin-resistant Staphylococcus aureus era. Eur J Clin Microbiol Infect Dis. 2014. doi:10.1007/s10096-014-2237-1.
7. Vyas K, Hospenthal DR, Mende K, Crum-Cianflone NF. Recurrent community-acquired methicillin-resistant Staphylococcus aureus infections in an urban HIV clinic. J Clin Microbiol Infect Dis. 2015;34(2):36–47. doi:10.1099/cmm.0.0081-0.
8. Crum-Cianflone N, Weeks J, Bavarro M. Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDs. 2009;23(7):499–502. doi:10.1089/apc.2008.0240.
9. Vyas K, Shadyab AH, Lin CD, Crum-Cianflone NF. Trends and Factors Associated with Initial and Recurrent Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft-Tissue Infections among HIV-Infected Persons: An 18-Year Study. Journal of the International Association of Providers of AIDS Care. 2013. doi:10.1177/2325957412473780.
10. Skiest D, Brown K, Hester J, Moore T, Crosby C, Musa H, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 2006;7(6):361–8. doi:10.1111/j.1468-1293.2006.00394.x.
11. Cox DR. Regression models and life tables. JR Stat Soc B. 1972;34(2):187–220.
12. Cox DR, Snell EJ. A general definition of residuals (with discussion). J R Stat Soc Ser B. 1968;30:284–75.
13. Cleves M, Gould W, Gutierrez R, Marchenko Y. An Introduction to Survival Analysis Using Stata. 3rd ed. College Station, TX: Stata Press; 2010.
14. Hosmer D, Lemeshow S. Applied survival analysis: regression modeling of time to event data. Hoboken, NJ: Wiley; 2011.
15. Kallen AJ, Mu Y, Bulens S, Reingold A, Pett S, Gershman K, et al. Health-care associated invasive MRSA infections, 2005–2008. JAMA. 2010;303(6):641–8. doi:10.1001/jama.2010.1115.
16. Hemmige V, McNulty M, Silverman E, David MZ. Predictors of skin and soft tissue infections in HIV-infected patients in the community-associated methicillin-resistant Staphylococcus aureus era. Eur J Clin Microbiol Infect Dis. 2014. doi:10.1007/s10096-014-2237-1.
17. Hosmer D, Lemeshow S. Applied survival analysis: regression modeling of time to event data. Hoboken, NJ: Wiley; 2011.